UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 174

Sortiert nach

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis

Neurochemical research, 2014-10, Vol.39 (10), p.2008-2017

2014

Link zum Volltext

Verfügbarkeit prüfen

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

The Journal of pharmacology and experimental therapeutics, 2007-08, Vol.322 (2), p.862

2007

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist

Journal of medicinal chemistry, 2005-12, Vol.48 (24), p.7517-7519

2005

Link zum Volltext

Verfügbarkeit prüfen

Constitutively Active Mutants of the Histamine H1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

Molecular pharmacology, 2008-01, Vol.73 (1), p.94

2008

Link zum Volltext

Verfügbarkeit prüfen

Optimization of isochromanone based urotensin II receptor agonists

Bioorganic & medicinal chemistry, 2010-07, Vol.18 (13), p.4844-4854

2010

Link zum Volltext

Verfügbarkeit prüfen

Identification of novel subtype selective RAR agonists

Biochemical pharmacology, 2005-12, Vol.71 (1), p.156-162

2005

Link zum Volltext

Verfügbarkeit prüfen

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day

Schizophrenia research, 2012-11, Vol.141 (2), p.144-152

2012

Link zum Volltext

Verfügbarkeit prüfen

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day

Schizophrenia research, 2012-11, Vol.141 (2-3), p.144-152

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist

The Journal of pharmacology and experimental therapeutics, 2004-09, Vol.310 (3), p.943

2004

Link zum Volltext

Verfügbarkeit prüfen

Stereoselective Epoxidation of Phe-Gly and Phe-Phe Vinyl Isosteres

Journal of organic chemistry, 1994-03, Vol.59 (5), p.1139-1148

1994

Link zum Volltext

Verfügbarkeit prüfen

Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios

Behavioural pharmacology, 2013-10, Vol.24 (7), p.628

2013

Link zum Volltext

Verfügbarkeit prüfen

The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons

Naunyn-Schmiedeberg's archives of pharmacology, 1993-04, Vol.347 (4), p.353-362

1993

Link zum Volltext

Verfügbarkeit prüfen

Discovery of an Ectopic Activation Site on the M 1 Muscarinic Receptor

Molecular pharmacology, 2002-06, Vol.61 (6), p.1297-1302

2002

Link zum Volltext

Verfügbarkeit prüfen

II. In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors

JOURNAL OF NEURAL TRANSMISSION, 2011-11, Vol.118 (11), p.1523-1533

2011

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Structure−Activity Analysis of Isoform-Selective Retinoic Acid Receptor β Ligands

Journal of medicinal chemistry, 2009-03, Vol.52 (6), p.1540-1545

2009

Link zum Volltext

Verfügbarkeit prüfen

Design, parallel synthesis and SAR of novel urotensin II receptor agonists

European journal of medicinal chemistry, 2007-02, Vol.42 (2), p.276-285

2007

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the Binding Site of the Histamine H3 Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl)cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)- cyclopropylamine

Journal of medicinal chemistry, 1999-04, Vol.42 (7), p.1115-1122

1999

Link zum Volltext

Verfügbarkeit prüfen

1 The Chemistry and Biochemistry of C-Nucleosides and C-Arylglycosides

Progress in Medicinal Chemistry, 1985, Vol.22, p.1-65

1985

Link zum Volltext

Verfügbarkeit prüfen

Analysis of molecular determinants of affinity and relative efficacy of a series of R ‐ and S ‐2‐(dipropylamino)tetralins at the 5‐HT 1A serotonin receptor

British journal of pharmacology, 2009-01, Vol.138 (6), p.1129-1139

2009

Link zum Volltext

Verfügbarkeit prüfen

Constitutively Active Mutants of the Histamine H 1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

Molecular pharmacology, 2008-01, Vol.73 (1), p.94-103

2008

Link zum Volltext

Verfügbarkeit prüfen

Novel Potent and Efficacious Nonpeptidic Urotensin II Receptor Agonists

Journal of medicinal chemistry, 2006-04, Vol.49 (7), p.2232-2240

2006

Link zum Volltext

Verfügbarkeit prüfen

8-Hydroxy-2-(dipropylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist

Journal of medicinal chemistry, 1981-08, Vol.24 (8), p.921-923

1981

Link zum Volltext

Verfügbarkeit prüfen

Base-Catalyzed cyclization of N-propargylamides to oxazoles

Journal of heterocyclic chemistry, 1989-03, Vol.26 (2), p.269-275

1989

Link zum Volltext

Verfügbarkeit prüfen

3-Heteroaryl-Substituted Quinuclidin-3-ol and Quinuclidin-2-ene Derivatives as Muscarinic Antagonists. Synthesis and Structure-Activity Relationships

Journal of medicinal chemistry, 1995-02, Vol.38 (3), p.473-487

1995

Link zum Volltext

Verfügbarkeit prüfen

Isochromanone-based urotensin-II receptor agonists

Bioorganic & medicinal chemistry, 2005-04, Vol.13 (8), p.3057-3068

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(164)
Mit Volltextzugriff
(157)

Publikationsform

Artikel
(172)
Buchkapitel
(2)

Sprache

Englisch
(174)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(99)
Life Sciences & Biomedicine
(81)
Animals
(79)
Pharmacology & Pharmacy
(71)
Rats
(56)
Chemistry
(55)
Chemistry, Medicinal
(50)
Male
(46)
Biological And Medical Sciences
(45)
Medical Sciences
(43)
Structure-Activity Relationship
(42)
Pharmacology. Drug Treatments
(41)
Organic Chemistry
(38)
Neuropharmacology
(36)
Exact Sciences And Technology
(34)
Neurotransmitters. Neurotransmission. Receptors
(33)
Preparations And Properties
(30)
Stereoisomerism
(30)
Physical Sciences
(29)
Humans
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist

Constitutively Active Mutants of the Histamine H1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

Optimization of isochromanone based urotensin II receptor agonists

Identification of novel subtype selective RAR agonists

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day

Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist

Stereoselective Epoxidation of Phe-Gly and Phe-Phe Vinyl Isosteres

Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios

The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons

Discovery of an Ectopic Activation Site on the M 1 Muscarinic Receptor

II. In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors

Design, Synthesis, and Structure−Activity Analysis of Isoform-Selective Retinoic Acid Receptor β Ligands

Design, parallel synthesis and SAR of novel urotensin II receptor agonists

Characterization of the Binding Site of the Histamine H3 Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl)cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)- cyclopropylamine

1 The Chemistry and Biochemistry of C-Nucleosides and C-Arylglycosides

Analysis of molecular determinants of affinity and relative efficacy of a series of R ‐ and S ‐2‐(dipropylamino)tetralins at the 5‐HT 1A serotonin receptor

Constitutively Active Mutants of the Histamine H 1 Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

Novel Potent and Efficacious Nonpeptidic Urotensin II Receptor Agonists

8-Hydroxy-2-(dipropylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist

Base-Catalyzed cyclization of N-propargylamides to oxazoles

3-Heteroaryl-Substituted Quinuclidin-3-ol and Quinuclidin-2-ene Derivatives as Muscarinic Antagonists. Synthesis and Structure-Activity Relationships

Isochromanone-based urotensin-II receptor agonists

Suchergebnisse filtern